All stock lists
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
441.60+7.36 (+1.69%)
Insider Score
––Not scored
MDGL Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
MDGL Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 364.25 M | 311.34 M | 321.08 M | 287.27 M | 212.80 M | 137.25 M |
| Revenue Growth (YoY) | 71.17 % | 126.84 % | 210.77 % | 362.03 % | 1353.76 % | — |
| Cost of Revenue | 40.01 M | 26.85 M | 24.45 M | 18.12 M | 9.06 M | 4.51 M |
| Gross Profit | 324.25 M | 284.49 M | 296.63 M | 269.15 M | 203.74 M | 132.74 M |
| SG&A Expense | 289.38 M | 268.52 M | 239.98 M | 209.12 M | 196.86 M | 167.88 M |
| R&D Expense | 91.18 M | 108.69 M | 116.27 M | 174.00 M | 54.08 M | 44.17 M |
| Operating Expenses | 380.55 M | 377.21 M | 356.24 M | 383.12 M | 250.94 M | 212.05 M |
| Operating Income | -56.31 M | -92.72 M | -59.61 M | -113.97 M | -47.20 M | -79.31 M |
| Pretax Income | -57.94 M | -94.39 M | -58.58 M | -114.19 M | -42.28 M | -73.24 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -57.94 M | -94.39 M | -58.58 M | -114.19 M | -42.28 M | -73.24 M |
| EPS (Basic) | -1.99 | -3.25 | -2.57 | -5.08 | -1.90 | -3.32 |
| EPS (Diluted) | -1.99 | -3.25 | -2.57 | -5.08 | -1.90 | -3.32 |
| Shares Outstanding | 29.15 M | 29.03 M | 22.43 M | 22.48 M | 22.21 M | 22.09 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.